Fig. 3

In vitro efficacy of Bm@PT/Enz-miR26a. (A–D) MiR26a and Enz synergistically inhibited CRPC cell proliferation. Significant decrease in cell viability when C4-2B and C4-2B EnzR cells were treated with Bm@PT/Enz-miR26a for 48 h compared with other groups (Enz: 0 ∼ 200 µg·mL^− 1, miR26a: 0 ∼ 2 µg·mL^− 1). n = 3, mean ± SD. (E) The representative results of apoptosis of C4-2B EnzR cells treated with each group for 48 h. (Enz: 30 µg·mL^− 1, miR26a: 0.25 µg·mL^− 1). (F) Statistical results of cell apoptosis in each group. n = 3, mean ± SD, ***p < 0.001, ****p < 0.0001, one-way ANOVA. (G) Combination therapy with miR26a and Enz induced G0/G1 cell cycle arrest (Enz: 25 µg·mL^− 1, miR26a: 0.2 µg·mL^− 1). (H–I) Microscope images of anti-migration effects and anti-invasion effects in each group (visualized with 0.1% crystal violet, scale bar: 50 μm). C4-2B EnzR cells were co-incubated with each group for 24 h (anti-migration assay) and 48 h (anti-invasion assay), respectively (Enz: 50 µg·mL^− 1, miR26a: 0.5 µg·mL^− 1)